nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—Thalidomide—leprosy	0.157	0.204	CbGbCtD
Sulindac—CYP1A1—Thalidomide—leprosy	0.133	0.172	CbGbCtD
Sulindac—PTGS1—Thalidomide—leprosy	0.133	0.172	CbGbCtD
Sulindac—PTGS2—Dapsone—leprosy	0.126	0.163	CbGbCtD
Sulindac—PTGS1—Dapsone—leprosy	0.106	0.138	CbGbCtD
Sulindac—CYP1A2—Thalidomide—leprosy	0.0593	0.0769	CbGbCtD
Sulindac—CYP1A2—Rifampicin—leprosy	0.0574	0.0745	CbGbCtD
Sulindac—AKR1B1—sciatic nerve—leprosy	0.0303	0.319	CbGeAlD
Sulindac—AKR1B1—peripheral nervous system—leprosy	0.0116	0.122	CbGeAlD
Sulindac—Nephrotic syndrome—Dapsone—leprosy	0.00533	0.0532	CcSEcCtD
Sulindac—MAPK3—blood vessel—leprosy	0.00515	0.0543	CbGeAlD
Sulindac—Gastrointestinal perforation—Thalidomide—leprosy	0.00505	0.0504	CcSEcCtD
Sulindac—PTGDR2—tendon—leprosy	0.00471	0.0496	CbGeAlD
Sulindac—AKR1B1—eye—leprosy	0.00378	0.0398	CbGeAlD
Sulindac—Proteinuria—Dapsone—leprosy	0.00293	0.0293	CcSEcCtD
Sulindac—Protein urine present—Dapsone—leprosy	0.00289	0.0288	CcSEcCtD
Sulindac—PTGS2—hindlimb—leprosy	0.0028	0.0295	CbGeAlD
Sulindac—MAPK3—eye—leprosy	0.00274	0.0289	CbGeAlD
Sulindac—PPARD—Pyruvate metabolism and Citric Acid (TCA) cycle—SDHD—leprosy	0.00254	0.0745	CbGpPWpGaD
Sulindac—AKR1B1—tendon—leprosy	0.00251	0.0264	CbGeAlD
Sulindac—PTGS2—appendage—leprosy	0.0024	0.0253	CbGeAlD
Sulindac—MAPK3—skin of body—leprosy	0.00239	0.0251	CbGeAlD
Sulindac—CYP1A1—skin epidermis—leprosy	0.00238	0.0251	CbGeAlD
Sulindac—AKR1B1—testis—leprosy	0.00207	0.0218	CbGeAlD
Sulindac—AKR1B1—nervous system—leprosy	0.00204	0.0214	CbGeAlD
Sulindac—PTGS2—skin epidermis—leprosy	0.002	0.0211	CbGeAlD
Sulindac—PPARD—tendon—leprosy	0.00197	0.0207	CbGeAlD
Sulindac—MAPK3—tendon—leprosy	0.00182	0.0191	CbGeAlD
Sulindac—Stupor—Thalidomide—leprosy	0.00176	0.0176	CcSEcCtD
Sulindac—Neuritis—Thalidomide—leprosy	0.00176	0.0176	CcSEcCtD
Sulindac—Cholestasis—Thalidomide—leprosy	0.00174	0.0173	CcSEcCtD
Sulindac—Pleural effusion—Thalidomide—leprosy	0.00172	0.0172	CcSEcCtD
Sulindac—Muscular weakness—Dapsone—leprosy	0.00165	0.0165	CcSEcCtD
Sulindac—PPARD—testis—leprosy	0.00163	0.0172	CbGeAlD
Sulindac—PPARD—nervous system—leprosy	0.0016	0.0169	CbGeAlD
Sulindac—Pancreatitis—Dapsone—leprosy	0.00158	0.0158	CcSEcCtD
Sulindac—MAPK3—testis—leprosy	0.0015	0.0158	CbGeAlD
Sulindac—Proteinuria—Thalidomide—leprosy	0.0015	0.015	CcSEcCtD
Sulindac—Protein urine present—Thalidomide—leprosy	0.00148	0.0148	CcSEcCtD
Sulindac—MAPK3—nervous system—leprosy	0.00148	0.0155	CbGeAlD
Sulindac—Photosensitivity reaction—Dapsone—leprosy	0.00147	0.0147	CcSEcCtD
Sulindac—Neuropathy peripheral—Dapsone—leprosy	0.00141	0.0141	CcSEcCtD
Sulindac—Leukocytosis—Thalidomide—leprosy	0.0014	0.014	CcSEcCtD
Sulindac—PTGS1—blood vessel—leprosy	0.0014	0.0147	CbGeAlD
Sulindac—Hearing impaired—Thalidomide—leprosy	0.00138	0.0138	CcSEcCtD
Sulindac—PTGS2—blood vessel—leprosy	0.00134	0.0141	CbGeAlD
Sulindac—Hyperkalaemia—Thalidomide—leprosy	0.00129	0.0129	CcSEcCtD
Sulindac—Depressed level of consciousness—Thalidomide—leprosy	0.00127	0.0127	CcSEcCtD
Sulindac—Colitis—Thalidomide—leprosy	0.00127	0.0126	CcSEcCtD
Sulindac—Aplastic anaemia—Thalidomide—leprosy	0.00124	0.0124	CcSEcCtD
Sulindac—Tinnitus—Dapsone—leprosy	0.00121	0.012	CcSEcCtD
Sulindac—Gynaecomastia—Thalidomide—leprosy	0.00118	0.0118	CcSEcCtD
Sulindac—Photosensitivity—Thalidomide—leprosy	0.00109	0.0109	CcSEcCtD
Sulindac—Gastroenteritis—Thalidomide—leprosy	0.00108	0.0108	CcSEcCtD
Sulindac—Vascular purpura—Thalidomide—leprosy	0.00107	0.0107	CcSEcCtD
Sulindac—Vision blurred—Dapsone—leprosy	0.00106	0.0106	CcSEcCtD
Sulindac—Cardiac failure congestive—Thalidomide—leprosy	0.00105	0.0105	CcSEcCtD
Sulindac—Dermatitis exfoliative—Thalidomide—leprosy	0.00101	0.0101	CcSEcCtD
Sulindac—Vertigo—Dapsone—leprosy	0.00101	0.0101	CcSEcCtD
Sulindac—Visual disturbance—Thalidomide—leprosy	0.00101	0.0101	CcSEcCtD
Sulindac—Purpura—Thalidomide—leprosy	0.000992	0.00991	CcSEcCtD
Sulindac—PPARD—The citric acid (TCA) cycle and respiratory electron transport—SDHD—leprosy	0.000985	0.0289	CbGpPWpGaD
Sulindac—Arthritis—Thalidomide—leprosy	0.000984	0.00983	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000957	0.00955	CcSEcCtD
Sulindac—Tachycardia—Dapsone—leprosy	0.000896	0.00895	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000861	0.0086	CcSEcCtD
Sulindac—Muscular weakness—Thalidomide—leprosy	0.000844	0.00842	CcSEcCtD
Sulindac—Insomnia—Dapsone—leprosy	0.000831	0.00829	CcSEcCtD
Sulindac—Eosinophilia—Thalidomide—leprosy	0.000819	0.00817	CcSEcCtD
Sulindac—Bronchospasm—Thalidomide—leprosy	0.000813	0.00812	CcSEcCtD
Sulindac—Pancreatitis—Thalidomide—leprosy	0.000811	0.00809	CcSEcCtD
Sulindac—Pancytopenia—Thalidomide—leprosy	0.000785	0.00784	CcSEcCtD
Sulindac—Neutropenia—Thalidomide—leprosy	0.000773	0.00772	CcSEcCtD
Sulindac—Photosensitivity reaction—Thalidomide—leprosy	0.000755	0.00754	CcSEcCtD
Sulindac—Gastrointestinal pain—Dapsone—leprosy	0.000751	0.0075	CcSEcCtD
Sulindac—Hyperglycaemia—Thalidomide—leprosy	0.000746	0.00745	CcSEcCtD
Sulindac—Pneumonia—Thalidomide—leprosy	0.000741	0.0074	CcSEcCtD
Sulindac—CYP1A1—skin of body—leprosy	0.000738	0.00777	CbGeAlD
Sulindac—Depression—Thalidomide—leprosy	0.000735	0.00734	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000731	0.0073	CcSEcCtD
Sulindac—Body temperature increased—Dapsone—leprosy	0.000726	0.00725	CcSEcCtD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000725	0.0213	CbGpPWpGaD
Sulindac—Renal failure—Thalidomide—leprosy	0.000725	0.00724	CcSEcCtD
Sulindac—Neuropathy peripheral—Thalidomide—leprosy	0.000723	0.00722	CcSEcCtD
Sulindac—Stomatitis—Thalidomide—leprosy	0.000718	0.00717	CcSEcCtD
Sulindac—ALB—testis—leprosy	0.000717	0.00755	CbGeAlD
Sulindac—Conjunctivitis—Thalidomide—leprosy	0.000716	0.00715	CcSEcCtD
Sulindac—Sweating—Thalidomide—leprosy	0.000707	0.00706	CcSEcCtD
Sulindac—Haematuria—Thalidomide—leprosy	0.000703	0.00702	CcSEcCtD
Sulindac—Epistaxis—Thalidomide—leprosy	0.000695	0.00694	CcSEcCtD
Sulindac—Agranulocytosis—Thalidomide—leprosy	0.000688	0.00687	CcSEcCtD
Sulindac—Hepatitis—Thalidomide—leprosy	0.000662	0.00661	CcSEcCtD
Sulindac—PTGS1—skin of body—leprosy	0.000648	0.00683	CbGeAlD
Sulindac—Visual impairment—Thalidomide—leprosy	0.000638	0.00637	CcSEcCtD
Sulindac—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—leprosy	0.00063	0.0185	CbGpPWpGaD
Sulindac—Erythema multiforme—Thalidomide—leprosy	0.000626	0.00625	CcSEcCtD
Sulindac—PTGS2—skin of body—leprosy	0.00062	0.00653	CbGeAlD
Sulindac—Tinnitus—Thalidomide—leprosy	0.000617	0.00616	CcSEcCtD
Sulindac—MAPK3—MAP kinase activation in TLR cascade—RIPK2—leprosy	0.000597	0.0175	CbGpPWpGaD
Sulindac—Chills—Thalidomide—leprosy	0.000594	0.00593	CcSEcCtD
Sulindac—Arrhythmia—Thalidomide—leprosy	0.000591	0.0059	CcSEcCtD
Sulindac—Alopecia—Thalidomide—leprosy	0.000585	0.00584	CcSEcCtD
Sulindac—Vomiting—Dapsone—leprosy	0.000584	0.00583	CcSEcCtD
Sulindac—Headache—Dapsone—leprosy	0.000575	0.00575	CcSEcCtD
Sulindac—Flatulence—Thalidomide—leprosy	0.000568	0.00567	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000566	0.0166	CbGpPWpGaD
Sulindac—Tension—Thalidomide—leprosy	0.000565	0.00564	CcSEcCtD
Sulindac—Dysgeusia—Thalidomide—leprosy	0.000564	0.00563	CcSEcCtD
Sulindac—Nervousness—Thalidomide—leprosy	0.000559	0.00559	CcSEcCtD
Sulindac—Nausea—Dapsone—leprosy	0.000545	0.00545	CcSEcCtD
Sulindac—Vision blurred—Thalidomide—leprosy	0.000543	0.00542	CcSEcCtD
Sulindac—MAPK3—MAP kinase activation in TLR cascade—NOD2—leprosy	0.000541	0.0159	CbGpPWpGaD
Sulindac—Ill-defined disorder—Thalidomide—leprosy	0.000534	0.00534	CcSEcCtD
Sulindac—Anaemia—Thalidomide—leprosy	0.000532	0.00532	CcSEcCtD
Sulindac—Angioedema—Thalidomide—leprosy	0.000526	0.00526	CcSEcCtD
Sulindac—Malaise—Thalidomide—leprosy	0.000519	0.00519	CcSEcCtD
Sulindac—Vertigo—Thalidomide—leprosy	0.000518	0.00517	CcSEcCtD
Sulindac—Syncope—Thalidomide—leprosy	0.000517	0.00516	CcSEcCtD
Sulindac—Leukopenia—Thalidomide—leprosy	0.000516	0.00515	CcSEcCtD
Sulindac—Palpitations—Thalidomide—leprosy	0.000509	0.00508	CcSEcCtD
Sulindac—Loss of consciousness—Thalidomide—leprosy	0.000506	0.00506	CcSEcCtD
Sulindac—Convulsion—Thalidomide—leprosy	0.000499	0.00498	CcSEcCtD
Sulindac—Hypertension—Thalidomide—leprosy	0.000497	0.00497	CcSEcCtD
Sulindac—PTGS1—tendon—leprosy	0.000494	0.0052	CbGeAlD
Sulindac—Chest pain—Thalidomide—leprosy	0.00049	0.0049	CcSEcCtD
Sulindac—Arthralgia—Thalidomide—leprosy	0.00049	0.0049	CcSEcCtD
Sulindac—Myalgia—Thalidomide—leprosy	0.00049	0.0049	CcSEcCtD
Sulindac—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—leprosy	0.000488	0.0143	CbGpPWpGaD
Sulindac—Discomfort—Thalidomide—leprosy	0.000485	0.00484	CcSEcCtD
Sulindac—MAPK3—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.000472	0.0139	CbGpPWpGaD
Sulindac—PTGS2—tendon—leprosy	0.000472	0.00497	CbGeAlD
Sulindac—Oedema—Thalidomide—leprosy	0.00047	0.00469	CcSEcCtD
Sulindac—Shock—Thalidomide—leprosy	0.000463	0.00462	CcSEcCtD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.00046	0.0135	CbGpPWpGaD
Sulindac—Thrombocytopenia—Thalidomide—leprosy	0.00046	0.0046	CcSEcCtD
Sulindac—Tachycardia—Thalidomide—leprosy	0.000459	0.00458	CcSEcCtD
Sulindac—CYP1A1—nervous system—leprosy	0.000457	0.00481	CbGeAlD
Sulindac—Hyperhidrosis—Thalidomide—leprosy	0.000454	0.00454	CcSEcCtD
Sulindac—Anorexia—Thalidomide—leprosy	0.000448	0.00447	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000447	0.0131	CbGpPWpGaD
Sulindac—Hypotension—Thalidomide—leprosy	0.000439	0.00439	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Thalidomide—leprosy	0.000428	0.00428	CcSEcCtD
Sulindac—MAPK3—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000428	0.0126	CbGpPWpGaD
Sulindac—MAPK3—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000427	0.0125	CbGpPWpGaD
Sulindac—Insomnia—Thalidomide—leprosy	0.000425	0.00425	CcSEcCtD
Sulindac—MAPK3—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000423	0.0124	CbGpPWpGaD
Sulindac—Paraesthesia—Thalidomide—leprosy	0.000422	0.00422	CcSEcCtD
Sulindac—Dyspnoea—Thalidomide—leprosy	0.000419	0.00419	CcSEcCtD
Sulindac—Somnolence—Thalidomide—leprosy	0.000418	0.00417	CcSEcCtD
Sulindac—MAPK3—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000416	0.0122	CbGpPWpGaD
Sulindac—Dyspepsia—Thalidomide—leprosy	0.000414	0.00413	CcSEcCtD
Sulindac—AKR1B1—Metabolism—SDHD—leprosy	0.00041	0.012	CbGpPWpGaD
Sulindac—PTGS1—testis—leprosy	0.000409	0.0043	CbGeAlD
Sulindac—Decreased appetite—Thalidomide—leprosy	0.000409	0.00408	CcSEcCtD
Sulindac—MAPK3—TCR Signaling Pathway—RIPK2—leprosy	0.000408	0.012	CbGpPWpGaD
Sulindac—Fatigue—Thalidomide—leprosy	0.000405	0.00405	CcSEcCtD
Sulindac—Constipation—Thalidomide—leprosy	0.000402	0.00401	CcSEcCtD
Sulindac—PTGS1—nervous system—leprosy	0.000401	0.00422	CbGeAlD
Sulindac—MAPK3—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.000401	0.0118	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—CD8A—leprosy	0.000396	0.0116	CbGpPWpGaD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000394	0.0116	CbGpPWpGaD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000394	0.0116	CbGpPWpGaD
Sulindac—Feeling abnormal—Thalidomide—leprosy	0.000387	0.00387	CcSEcCtD
Sulindac—MAPK3—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000387	0.0114	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Thalidomide—leprosy	0.000384	0.00384	CcSEcCtD
Sulindac—MAPK3—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000384	0.0113	CbGpPWpGaD
Sulindac—PTGS2—nervous system—leprosy	0.000383	0.00404	CbGeAlD
Sulindac—MAPK3—MyD88-independent cascade—RIPK2—leprosy	0.000378	0.0111	CbGpPWpGaD
Sulindac—MAPK3—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000377	0.0111	CbGpPWpGaD
Sulindac—Urticaria—Thalidomide—leprosy	0.000373	0.00373	CcSEcCtD
Sulindac—Body temperature increased—Thalidomide—leprosy	0.000372	0.00371	CcSEcCtD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000369	0.0108	CbGpPWpGaD
Sulindac—MAPK3—Cellular roles of Anthrax toxin—TNF—leprosy	0.000367	0.0108	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000364	0.0107	CbGpPWpGaD
Sulindac—MAPK3—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000357	0.0105	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—RIPK2—leprosy	0.000353	0.0104	CbGpPWpGaD
Sulindac—Hypersensitivity—Thalidomide—leprosy	0.000346	0.00346	CcSEcCtD
Sulindac—MAPK3—MyD88-independent cascade—NOD2—leprosy	0.000343	0.0101	CbGpPWpGaD
Sulindac—MAPK3—Activated TLR4 signalling—RIPK2—leprosy	0.00034	0.00998	CbGpPWpGaD
Sulindac—MAPK3—Activated TLR4 signalling—TLR2—leprosy	0.00034	0.00998	CbGpPWpGaD
Sulindac—Asthenia—Thalidomide—leprosy	0.000337	0.00337	CcSEcCtD
Sulindac—Pruritus—Thalidomide—leprosy	0.000333	0.00332	CcSEcCtD
Sulindac—MAPK3—IFN-gamma pathway—IFNG—leprosy	0.000332	0.00975	CbGpPWpGaD
Sulindac—Diarrhoea—Thalidomide—leprosy	0.000322	0.00321	CcSEcCtD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.00032	0.00939	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.00032	0.00939	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—NOD2—leprosy	0.00032	0.00938	CbGpPWpGaD
Sulindac—MAPK3—IL-5 Signaling Pathway—IL2—leprosy	0.000313	0.00918	CbGpPWpGaD
Sulindac—Dizziness—Thalidomide—leprosy	0.000311	0.0031	CcSEcCtD
Sulindac—PTGS1—Overview of nanoparticle effects—TNF—leprosy	0.00031	0.00908	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—CD8A—leprosy	0.000309	0.00908	CbGpPWpGaD
Sulindac—MAPK3—Activated TLR4 signalling—NOD2—leprosy	0.000308	0.00905	CbGpPWpGaD
Sulindac—MAPK3—IL-2 Signaling Pathway—IL2—leprosy	0.000301	0.00883	CbGpPWpGaD
Sulindac—Vomiting—Thalidomide—leprosy	0.000299	0.00298	CcSEcCtD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	0.000298	0.00874	CbGpPWpGaD
Sulindac—Rash—Thalidomide—leprosy	0.000296	0.00296	CcSEcCtD
Sulindac—Dermatitis—Thalidomide—leprosy	0.000296	0.00296	CcSEcCtD
Sulindac—Headache—Thalidomide—leprosy	0.000295	0.00294	CcSEcCtD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.00029	0.00851	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000288	0.00846	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000285	0.00836	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—TLR2—leprosy	0.000285	0.00836	CbGpPWpGaD
Sulindac—Nausea—Thalidomide—leprosy	0.000279	0.00279	CcSEcCtD
Sulindac—MAPK3—TGF-beta Receptor Signaling—IFNG—leprosy	0.000277	0.00812	CbGpPWpGaD
Sulindac—MAPK3—IL2-mediated signaling events—IFNG—leprosy	0.000277	0.00812	CbGpPWpGaD
Sulindac—MAPK3—Interleukin-2 signaling—IL2—leprosy	0.000275	0.00807	CbGpPWpGaD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000271	0.00794	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—NOD2—leprosy	0.000258	0.00758	CbGpPWpGaD
Sulindac—MAPK3—ATF-2 transcription factor network—IFNG—leprosy	0.000258	0.00757	CbGpPWpGaD
Sulindac—MAPK3—IL2-mediated signaling events—IL2—leprosy	0.000246	0.00722	CbGpPWpGaD
Sulindac—PTGS2—Overview of nanoparticle effects—TNF—leprosy	0.000246	0.00721	CbGpPWpGaD
Sulindac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000241	0.00706	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—IFNG—leprosy	0.000236	0.00692	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Telomerase—IFNG—leprosy	0.00023	0.00675	CbGpPWpGaD
Sulindac—SLC22A6—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000222	0.00651	CbGpPWpGaD
Sulindac—MAPK3—TWEAK Signaling Pathway—TNF—leprosy	0.000219	0.00643	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—IL2—leprosy	0.00021	0.00615	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Telomerase—IL2—leprosy	0.000205	0.006	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IFNG—leprosy	0.000198	0.00582	CbGpPWpGaD
Sulindac—MAPK3—Ceramide signaling pathway—TNF—leprosy	0.000197	0.00578	CbGpPWpGaD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—TNF—leprosy	0.000191	0.00559	CbGpPWpGaD
Sulindac—MAPK3—TGF-beta Receptor Signaling—TNF—leprosy	0.000179	0.00526	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—CD4—leprosy	0.000178	0.00521	CbGpPWpGaD
Sulindac—MAPK3—Cardiac Hypertrophic Response—TNF—leprosy	0.000177	0.00518	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—IL2—leprosy	0.000176	0.00517	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	0.000175	0.00514	CbGpPWpGaD
Sulindac—PPARD—Adipogenesis—TNF—leprosy	0.000174	0.0051	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000166	0.00487	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—RIPK2—leprosy	0.000165	0.00483	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—RIPK2—leprosy	0.000162	0.00475	CbGpPWpGaD
Sulindac—MAPK3—Corticotropin-releasing hormone—IL2—leprosy	0.000161	0.00471	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	0.000156	0.00457	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling in naïve CD8+ T cells—TNF—leprosy	0.000153	0.00448	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—HLA-DRB1—leprosy	0.000152	0.00446	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NOD2—leprosy	0.000149	0.00438	CbGpPWpGaD
Sulindac—PPARD—Metabolism—SDHD—leprosy	0.000149	0.00436	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IFNG—leprosy	0.000148	0.00435	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000148	0.00433	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CYLD—leprosy	0.000143	0.0042	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL2—leprosy	0.000141	0.00415	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IFNG—leprosy	0.00014	0.00412	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IFNG—leprosy	0.000139	0.00409	CbGpPWpGaD
Sulindac—MAPK3—Alzheimers Disease—TNF—leprosy	0.000132	0.00388	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL2—leprosy	0.000132	0.00386	CbGpPWpGaD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000126	0.00369	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—RIPK2—leprosy	0.000121	0.00355	CbGpPWpGaD
Sulindac—PTGS2—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000121	0.00355	CbGpPWpGaD
Sulindac—MAPK3—TNF alpha Signaling Pathway—TNF—leprosy	0.000117	0.00343	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC11A1—leprosy	0.000115	0.00338	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IFNG—leprosy	0.000113	0.00333	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	0.000113	0.00333	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC11A1—leprosy	0.000113	0.00331	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—CD4—leprosy	0.000112	0.00328	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IFNG—leprosy	0.000111	0.00327	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—IFNG—leprosy	0.000111	0.00326	CbGpPWpGaD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.000108	0.00316	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.000108	0.00315	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor—TNF—leprosy	0.000108	0.00315	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000106	0.00311	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	0.000102	0.00298	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL2—leprosy	0.000101	0.00296	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—TNF—leprosy	9.59e-05	0.00281	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	9.41e-05	0.00276	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—RIPK2—leprosy	9.23e-05	0.00271	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—TLR2—leprosy	9.23e-05	0.00271	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—TNF—leprosy	9.08e-05	0.00266	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—IL2—leprosy	9.04e-05	0.00265	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—TNF—leprosy	9.02e-05	0.00265	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IFNG—leprosy	9.01e-05	0.00264	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IFNG—leprosy	8.81e-05	0.00258	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNF—leprosy	8.41e-05	0.00247	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NOD2—leprosy	8.37e-05	0.00246	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CYLD—leprosy	8.34e-05	0.00245	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL2—leprosy	8.21e-05	0.00241	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—IL2—leprosy	7.97e-05	0.00234	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL2—leprosy	7.83e-05	0.0023	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IFNG—leprosy	7.42e-05	0.00218	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PARK2—leprosy	7.38e-05	0.00216	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TNF—leprosy	7.34e-05	0.00215	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TNF—leprosy	7.23e-05	0.00212	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—TNF—leprosy	7.21e-05	0.00212	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	6.85e-05	0.00201	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	6.85e-05	0.00201	CbGpPWpGaD
Sulindac—MAPK3—Disease—SLC11A1—leprosy	6.81e-05	0.002	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL2—leprosy	6.59e-05	0.00193	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TNF—leprosy	6.52e-05	0.00191	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC11A1—leprosy	5.86e-05	0.00172	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—leprosy	5.83e-05	0.00171	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—leprosy	5.7e-05	0.00167	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SDHD—leprosy	5.68e-05	0.00167	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TLR2—leprosy	5.38e-05	0.00158	CbGpPWpGaD
Sulindac—MAPK3—Immune System—RIPK2—leprosy	5.38e-05	0.00158	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NOD2—leprosy	4.87e-05	0.00143	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL2—leprosy	4.85e-05	0.00142	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SDHD—leprosy	4.51e-05	0.00132	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40LG—leprosy	4.12e-05	0.00121	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL2—leprosy	4.11e-05	0.00121	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD8A—leprosy	4.08e-05	0.0012	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC11A1—leprosy	4.05e-05	0.00119	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CD4—leprosy	4.02e-05	0.00118	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SDHD—leprosy	4e-05	0.00118	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—leprosy	3.88e-05	0.00114	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL2—leprosy	3.83e-05	0.00112	CbGpPWpGaD
Sulindac—ALB—Metabolism—SDHD—leprosy	3.65e-05	0.00107	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RIPK2—leprosy	3.48e-05	0.00102	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DRB1—leprosy	3.32e-05	0.000974	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—leprosy	3.05e-05	0.000895	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SDHD—leprosy	2.55e-05	0.000749	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—leprosy	2.42e-05	0.000711	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—leprosy	2.36e-05	0.000692	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD4—leprosy	2.34e-05	0.000687	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD4—leprosy	2.16e-05	0.000634	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—leprosy	2.15e-05	0.000632	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—leprosy	1.98e-05	0.00058	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—leprosy	1.39e-05	0.000409	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—leprosy	1.29e-05	0.000377	CbGpPWpGaD
